

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7727123

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
GLORIANA THERAPEUTICS	11/21/2022

RECEIVING PARTY DATA

Name:	SINFONIA BIOTHERAPEUTICS AB
Street Address:	HALSOVAGEN 7
City:	HUDDINGE
State/Country:	SWEDEN
Postal Code:	14157

PROPERTY NUMBERS Total: 23

Property Type	Number
Application Number:	17789653
Application Number:	12280772
Application Number:	17676085
Application Number:	13145669
Application Number:	14289956
Application Number:	14821498
Application Number:	15851741
Application Number:	17145877
Application Number:	13876088
Application Number:	15582761
Application Number:	17099356
Application Number:	17417067
Application Number:	10356264
Application Number:	13679529
Application Number:	11573773
Application Number:	09662183
Application Number:	09347613
Application Number:	10661984
Application Number:	11614599
Application Number:	12029917

PATENT

Property Type	Number
Application Number:	12632517
Application Number:	11573771
Application Number:	12672213

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4016606079

Email: alan@feeneylawgroup.com

Correspondent Name: ALAN F. FEENEY, ESQ.

Address Line 1: FEENEY IP LAW, 235 PROMENADE STREET, SUITE 485

Address Line 4: PROVIDENCE, RHODE ISLAND 02908

ATTORNEY DOCKET NUMBER:	GLOR_000
NAME OF SUBMITTER:	ALAN F. FEENEY, ESQ.
SIGNATURE:	/alan f feeney/
DATE SIGNED:	01/05/2023
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 4

source=Assignment_Glor2Sinf2Final#page1.tif

source=Assignment_Glor2Sinf2Final#page2.tif

source=Assignment_Glor2Sinf2Final#page3.tif

source=Assignment_Glor2Sinf2Final#page4.tif

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Gloriana Therapeutics located at 130 Franklin Street, Suite 2, Warren, Rhode Island (hereinafter referred to as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

Sinfonia Biotherapeutics AB
Hälsovägen 7
14157 Huddinge
SWEDEN

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to the inventions as set forth in the United States Patents and Patent Applications as set forth in SCHEDULE "A", as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified applications and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the Patent Cooperation Treaty, the Paris Convention and any other international agreement; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to

execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **Feeney IP Law** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **Feeney IP Law** do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

Executed this 21 day of November 2022.

Lars U. Wahlberg
LARS U. WAHLBERG
In His Capacity as CEO/President
Gloriana Therapeutics


State of RHODE ISLAND)
County of PROVIDENCE)

On 11/21/22, before me, Jennifer S. Hyde
Date Here insert Name and Title of the Officer (Notary Public)

personally appeared Dr. LARS U. WAHLBERG
Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/their executed the same in his/hcr/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY that the foregoing paragraph is true and correct.
WITNESS my hand and official seal.

Signature *Jennifer S. Hyde*

Signature of Notary Public

Place Notary Seal Above

Serial No.	Date of Filing	Patent No.	Issue Date	Title
17/789,653	6/28/2022	N/A	N/A	Mammalian Cells Secreting GDNF and Their Therapeutic Uses
12/280,772	2/27/2007	10,328,125	6/25/2019	Treatment for Neurological Disorders
17/676,085	2/18/2022	N/A	N/A	Therapeutic Protein Formulations
13/145,669	10/17/2011	8,741,340	6/3/2014	Cell Lines and Their Use in Encapsulated Cell Biodelivery
14/289,956	5/29/2014	9,121,037	9/1/2015	Cell Lines and Their Use in Encapsulated Cell Biodelivery
14/821,498	8/7/2015	9,884,023	2/6/2018	Cell Lines and Their Use in Encapsulated Cell Biodelivery
15/851,741	12/22/2017	10,888,526	1/12/2021	Cell Lines and Their Use in Encapsulated Cell Biodelivery
17/145,877	1/11/2021	N/A	N/A	Cell Lines and Their Use in Encapsulated Cell Biodelivery
13/876,088	6/17/2013	9,669,154	6/6/2017	Implantable Cell Device with Supportive and Radial Diffusive Scaffolding
15/582,761	4/30/2017	10,835,664	11/17/2020	Implantable Cell Device with Supportive and Radial Diffusive Scaffolding
17/099,356	11/16/2020	N/A	N/A	Implantable Cell Device with Supportive and Radial Diffusive Scaffolding
17/417,067	6/21/2021	N/A	N/A	Mammalian Cell Culture-Produced Neublabin Antibodies
17/676,085	2/18/2022	N/A	N/A	Therapeutic Protein Formulations
10/356,264	1/31/2003	7,442,370	10/28/2008	Polymer Conjugates of Mutated Neublabin
13/679,529	11/16/2012	9,138,461	9/22/2015	Methods for Increasing Vascularization
11/573,773	6/24/2007	8,263,553	9/11/2012	Neublabin Variants
09/662,183	9/15/2000	6,734,284	5/11/2004	Novel Neurotrophic Factors
09/347,613	7/2/1999	6,593,133	6/26/2003	Novel Neurotrophic Factors
10/661,984	9/12/2003	7,276,580	10/2/2007	Neutrophic Factors
11/614,599	12/21/2006	7,358,228	4/15/2008	Neutrophic Factors
12/029,917	2/12/2008	7,655,463	2/2/2010	Neutrophic Factors
12/632,517	12/7/2009	8,217,146	7/10/2012	Neutrophic Factors
11/573,771	12/14/2007	8,722,862	5/13/2014	Refolding Transforming Growth Factor Beta Family Proteins
12/672,213	1/13/2011	N/A	N/A	Anti-Neublabin Antibodies and Uses Thereof

"A"

PATENT